



## Erratum

## Erratum to “Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis” [EBioMedicine 2 (8), August 2015, 868–873]



Mamoudou Maiga<sup>a,b,1</sup>, Bintou Ahmadou Ahidjo<sup>a,c</sup>, Mariama C. Maiga<sup>a,c</sup>, Laurene Cheung<sup>a,c</sup>, Shaaretha Pelly<sup>a,c</sup>, Shichun Lun<sup>a</sup>, Flabou Bougoudogo<sup>b</sup>, William R. Bishai<sup>a,c,\*</sup>

<sup>a</sup> Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA

<sup>b</sup> Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali

<sup>c</sup> Howard Hughes Medical Institute, Chevy Chase, MD, USA

On page 867, third paragraph of the Introduction Section, the following sentence,

“In efforts to block pro-inflammatory responses, we recently showed that tofacitinib, a Janus kinase (JAK) inhibitor that was FDA-approved in 2012 for treating rheumatoid arthritis and ulcerative colitis (Traynor, 2012; Sandborn et al., 2012), blocked immune containment and promoted bacterial replication during chronic TB in the mouse paucibacillary model in the absence of anti-TB drugs (Maiga et al., 2012)”.

Should read:

“In efforts to block pro-inflammatory responses, we recently showed that tofacitinib, a Janus kinase (JAK) inhibitor that was FDA-approved in 2012 for treating rheumatoid arthritis (Traynor, 2012), and shown to induce clinical response and remission in patients with ulcerative colitis (Sandborn et al., 2012), blocked immune containment and promoted bacterial replication during chronic TB in the mouse paucibacillary model in the absence of anti-TB drugs (Maiga et al., 2012)”.

We regret the error.

DOI of original article: <http://dx.doi.org/10.1016/j.ebiom.2015.07.014>.

\* Corresponding author at: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1550 Orleans St., Room 103, Baltimore, MD 21231, USA.

E-mail address: [wbishai1@jhmi.edu](mailto:wbishai1@jhmi.edu) (W.R. Bishai).

<sup>1</sup> Current address: National Institute of Allergic and Infectious Diseases, DIR/LPD, Bethesda, Maryland, USA.